drugset / Trial / NCT02183532

Pharmacokinetics of Single and Multiple Oral Doses of BI 1356 in Healthy Chinese Volunteers

NCT02183532

Phase 1 Completed 12 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

Study to investigate the pharmacokinetics of BI 1356 after single and multiple oral doses of 5 mg in Chinese healthy subjects

Timeline

Start
2009-07
Primary completion
2009-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Linagliptin Small molecule 5 mg Oral

Indications

No indication recorded.